Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease

Completed · Not applicable

Conditions studied: Parkinson's Disease, Overactive Bladder

In brief

The purpose of this research study is to investigate the cognitive (thinking, memory, knowledge, intelligence) side effects of two medications commonly used to treat overactive bladder (OAB) symptoms in veteran patients with Parkinson's disease (PD) seen at the Philadelphia PADRECC.

Key facts

Study ID

NCT00892450

Run by

US Department of Veterans Affairs

People needed

12

Starts

2009-05-01

Expected to finish

2014-09-01

Last updated by the study team

2014-10-03

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of idiopathic PD (ICD9=332.0)
• MMSE 24, able to give informed consent and complete questionnaires and voiding diaries.
• Urological work-up within 3 months of enrollment to:
• Rule out treatable causes of urinary symptoms
• Urinalysis (UA)
• Post-void residual ultrasound (PVR)
• Urinary cytology
• Documented symptoms OAB on screening 3-day voiding diary:
• Average of 1 urgency episode / 24 hours, and
• Average of 8 micturitions / 24 hours
• Subjective complaints of symptoms for 3 months

You may not qualify if…

• Exposure to anticholinergics or antispasmodics within the last 4 weeks (among them: atropine, tolterodine, benztropine, trihexyphenidyl, dicyclomine, hyoscyamine, and scopolamine)
• Exposure to drugs with known effects on cognition (i.e. opioids, benzodiazepines or sedating antihistamines) within the last week
• Exposure to drugs contraindicated or cautioned in use with the 2 study medications (drugs that also use the cytochrome P450 enzyme, primarily CYP3A4). These include: ketoconazole, itraconazole, miconazole, erythromycin, clarithromycin, ritonavir, nelfinavir, nefazodone, flecainide, thioridazine and tricyclic antidepressants.
• Nonpharmacological treatment of OAB within the last 4 weeks (for example: biofeedback, physical therapy, acupuncture)
• Uncontrolled narrow angle glaucoma
• History of gastric or urinary retention / dysmotility (ulcerative colitis, myasthenia gravis and severe constipation)
• History of hepatic or renal impairment
• History of severe gastro-esophageal reflux disease and/or use of bisphosphonates, patients at risk for esophagitis
• Previous exposure to anticholinergic for OAB symptoms that resulted in side effects that caused cessation of the medication

Where it is running

• VA Medical Center, Philadelphia — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.